ライフサイエンスコーパス: podocalyxin

1 action (e.g., angiotensin converting enzyme, podocalyxin).

2 at) and recognized both rabbit PCLP1 and rat podocalyxin.

3 invasiveness in cancer cells overexpressing podocalyxin.

4 lylation of the major podocyte sialoprotein, podocalyxin.

5 gulation of synaptopodin, WT-1, nephrin, and podocalyxin.

6 te differentiation markers, synaptopodin and podocalyxin.

7 ll adhesion molecule 1 (GlyCAM-1), CD34, and podocalyxin.

8 nt the human homolog of rabbit PCLP1 and rat podocalyxin.

9 lated previously and confirmed recently that podocalyxin, a sialomucin, plays a major role in maintai

10 Overexpression of podocalyxin also affected transepithelial resistance and

11 her the highly conserved cytoplasmic tail of podocalyxin also contributes to the unique organization

12 n to its ectodomain, the cytoplasmic tail of podocalyxin also likely contributes to maintaining the u

13 sion pattern of apico-basal polarity markers Podocalyxin and Collagen IV.

14 ings reveal that a novel interaction between podocalyxin and dynamin-2 promotes migration and metasta

15 To assess its function, we cloned rat podocalyxin and examined the effects of its expression o

16 the cell periphery in a ternary complex with podocalyxin and ezrin, where it promotes TMV release.

17 on of the genes for NPHS1, NPHS2, CD2AP, and podocalyxin and may involve other genes yet to be implic

18 Podocytes in ectatic tubules expressed podocalyxin and podocin proteins but not nephrin, compat

19 By immunocytochemistry, it was shown that podocalyxin and the actin binding protein ezrin are co-e

20 interaction between the cytoplasmic tail of podocalyxin and the large GTPase dynamin-2 at its GTPase

21 n alpha3beta1 expression, as well as that of podocalyxin and the slit diaphragm component ZO-1.

22 Thus, CD34, podocalyxin, and endoglycan comprise a family of sialomu

23 ed renal histology, increased sialylation of podocalyxin, and increased Gne/Mnk protein expression an

24 ncluding WT-1, CALLA, C3b receptor, GLEPP-1, podocalyxin, and synaptopodin.

25 ccompanied by reduction of nephrin, podocin, podocalyxin, and Wilms tumor 1 proteins.

26 CD34 and podocalyxin are structurally related sialomucins, which

27 ed glomerular expression of both nephrin and podocalyxin as well as enhanced susceptibility to glomer

28 ith improved sialylation of both nephrin and podocalyxin, as well as reduced albuminuria compared wit

29 switch mechanism results in the retention of Podocalyxin at the ECM interface and the development ins

30 eatment with PAN increased the expression of podocalyxin at the protein and mRNA levels.

31 e two other members of this family (CD34 and podocalyxin) can function as a L-selectin ligand.

32 CRISPR/Cas9 knockout of podocalyxin causes junctional organization defects in po

33 y, membrane translocation, and reassembly of podocalyxin complexes controls epithelial cell polarizat

34 Endoglycan (EG) together with CD34 and podocalyxin comprise the CD34 family of sialomucins.

35 l gelatinase-associated lipocalin (NGAL) and podocalyxin, concomitant with upregulated renal gene exp

36 ial centrifugation revealed that some of the podocalyxin cosediments with actin filaments.

37 To determine the role of ezrin in these podocalyxin-dependent phenotypic events, we first confir

38 Moreover, depletion of podocalyxin did not alter actin dynamics or modulate Rac

39 RhoJ regulates the endosomal trafficking of podocalyxin during angiogenesis to control lumen formati

40 This podocalyxin-dynamin-2 interaction regulated microtubule

41 Pre-operative levels of podocalyxin EVs, urinary particle concentrations and miR

42 Podocalyxin expression also led to an increase in mitoge

43 ng differentiation-dependent upregulation of podocalyxin expression BASP1 occupancy of the podocalyxi

44 rization via Rac1 or RhoA, we did not detect podocalyxin-ezrin association in pancreatic cancer cells

45 Once formed, podocalyxin/ezrin complexes are very stable, because the

46 e findings reveal a novel mechanism by which podocalyxin facilitates pancreatic cancer cell migration

47 t phenotypic events, we first confirmed that podocalyxin formed a complex with ezrin in MCF7 and PC3

48 g Podocalyxin/NHERF1/Ezrin complex, removing Podocalyxin from the ECM-abutting cell surface and initi

49 These results provide direct evidence that podocalyxin functions as an antiadhesin that maintains a

50 ding of WT1 to conserved elements within the Podocalyxin gene promoter results in potent transcriptio

51 1 occupy the promoters of the Bak, c-myc and podocalyxin genes in podocyte precursor cells.

52 ns concentrate in the cilium, others such as podocalyxin/gp135 are excluded.

53 Depletion of podocalyxin in a hemispleen mouse model of pancreatic ca

54 aPod)) and a second that is heterozygous for podocalyxin in all tissues (Podxl(+/-)).

55 Here, we show that overexpression of podocalyxin in MCF7 breast cancer and PC3 prostate cance

56 Here, we investigate the role of podocalyxin in migration and metastasis of pancreatic ad

57 tion, and the specific expression pattern of Podocalyxin in the developing kidney mirrors that of WT1

58 ic acid prevented sialylation of nephrin and podocalyxin in the maturing podocyte where it is require

59 The mechanism through which podocalyxin increases cancer aggressiveness remains poor

60 In EcR-CHO cells, the expression level of podocalyxin induced by increasing levels of ecdysone ana

61 Podocalyxin is a major membrane protein of the glomerula

62 Podocalyxin is a type 1 transmembrane sialoprotein with

63 nd that the developmental timepoint at which podocalyxin is ablated (immature vs. mature podocytes) h

64 The sialoglycoprotein podocalyxin is absent in normal pancreas but is overexpr

65 Podocalyxin is an anti-adhesive transmembrane sialomucin

66 These data indicate that in podocytes, podocalyxin is complexed with ezrin, which mediates its

67 ssion of the nonciliary apical protein gp135/podocalyxin is greatly decreased.

68 Podocalyxin is immobilized by its PDZ interaction motif

69 These findings suggest that podocalyxin leads to increased in vitro migration and in

70 n factor-3 (Gdf3), oncostatin-M (OncoM), and podocalyxin like-1 (PODXL).

71 noncanonical EPO/EPOR response factors (e.g. podocalyxin like-1, tribbles 3, reactive oxygen species,

72 est region of allelic imbalance contains the podocalyxin-like (PODXL) gene, which we evaluate here as

73 Podocalyxin-like protein (PCLP) is a transmembrane sialo

74 teins, CD44, carcinoembryonic antigen (CEA), podocalyxin-like protein (PCLP), and melanoma cell adhes

75 ectively expressed in the early progenitors: podocalyxin-like protein (PODXL), alpha6-integrin (CD49f

76 r identified the embryonal carcinoma antigen podocalyxin-like protein 1 (PODXL), an anti-adhesive pro

77 zation of slit diaphragm components, whereas podocalyxin localization was preserved.

78 qQ > L, there was a significant reduction in podocalyxin mRNA as well as nephrin mRNA and protein lev

79 phosphorylates the apical identity-promoting Podocalyxin/NHERF1/Ezrin complex, removing Podocalyxin f

80 Podocalyxin (PC) is the major sialoglycoprotein expresse

81 Podocalyxin (PC), the major sialoprotein of glomerular e

82 on, as seen by failed localization of apical podocalyxin (PODXL) and basal actin.

83 Dominant and recessive mutations in podocalyxin (PODXL) are associated with human kidney dis

84 Rab11a is critical for apical delivery of podocalyxin (PODXL) during lumen formation in epithelial

85 53-mediated repression in this system is the podocalyxin (PODXL) gene.

86 Podocalyxin (Podxl) is broadly expressed on the luminal

87 The glycocalyx component and sialomucin podocalyxin (PODXL) is required for normal tissue develo

88 in primordial follicle formation, including podocalyxin (Podxl), PDGFR-beta, and a follistatin-domai

89 Pre-surgery podocalyxin-positive EV were significantly lower in pati

90 Most L-selectin ligands such as CD34 and podocalyxin present sulfated carbohydrate structures (6-

91 odocalyxin expression BASP1 occupancy of the podocalyxin promoter is reduced compared to that of WT1.

92 d have additive or repressive effects on the Podocalyxin promoter, depending on dosage.

93 il now there has been no direct evidence for podocalyxin's function.

94 sociated with adult-onset kidney disease and podocalyxin shedding into the urine is a common biomarke

95 ssay, CHO-K1 cells expressing high levels of podocalyxin showed complete inhibition of cell aggregati

96 of c-kit-positive cells expresses Flk-1 and podocalyxin, suggesting that this cell population includ

97 regarded as a cytoplasmic binding partner of podocalyxin that regulates actin polymerization via Rac1

98 cursors leads to the induction of endogenous Podocalyxin, the major structural membrane protein of gl

99 oJ are required for polarized trafficking of podocalyxin to the early apical surface--an important ev

100 Rabs and Rab effectors are used to regulate podocalyxin trafficking in two- versus three-dimensional

101 1, nephrin, glomerular epithelial protein 1, podocalyxin, vascular endothelial growth factor, and alp

102 Furthermore, expression of podocalyxin was associated with a changed ezrin subcellu

103 Podocalyxin was downregulated by 20% in newborn kidneys

104 The inhibitory effect of podocalyxin was reversed by treatment of the cells with

105 The glomerular glycoproteins nephrin and podocalyxin were hyposialylated in this unique murine mo

106 nderstood but may involve the interaction of podocalyxin with ezrin, an established mediator of metas

107 cell polarity requires apical trafficking of podocalyxin; yet the regulation of its transport is uncl